Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The interaction between smoking status and highly active antiretroviral therapy (HAART) use on the risk of Kaposi's sarcoma (KS) in a cohort of HIV-infected men.

Luu HN, Amirian ES, Scheurer ME.

Br J Cancer. 2013 Mar 19;108(5):1173-7. doi: 10.1038/bjc.2013.75. Epub 2013 Feb 19.

2.

Age patterns of Kaposi's sarcoma incidence in a cohort of HIV-infected men.

Luu HN, Amirian ES, Chiao EY, Scheurer ME.

Cancer Med. 2014 Dec;3(6):1635-43. doi: 10.1002/cam4.312. Epub 2014 Aug 20.

3.

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S; Swiss HIV Cohort.

J Natl Cancer Inst. 2005 Mar 16;97(6):425-32.

PMID:
15770006
4.

Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S, Jundt G, Mueller N, Clifford GM.

Br J Cancer. 2008 Sep 2;99(5):800-4. doi: 10.1038/sj.bjc.6604520. Epub 2008 Jul 29.

5.

The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.

Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD.

Cancer. 2004 Jun 15;100(12):2644-54.

6.

Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.

Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, Mermin J, Kaharuza F.

HIV Med. 2012 Mar;13(3):166-71. doi: 10.1111/j.1468-1293.2011.00955.x. Epub 2011 Nov 24.

7.

Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007.

Seaberg EC, Wiley D, Martínez-Maza O, Chmiel JS, Kingsley L, Tang Y, Margolick JB, Jacobson LP; Multicenter AIDS Cohort Study (MACS).

Cancer. 2010 Dec 1;116(23):5507-16. doi: 10.1002/cncr.25530. Epub 2010 Jul 29.

8.

Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.

Tam HK, Zhang ZF, Jacobson LP, Margolick JB, Chmiel JS, Rinaldo C, Detels R.

Int J Cancer. 2002 Apr 20;98(6):916-22.

10.

Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.

Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE.

Cochrane Database Syst Rev. 2014;(9):CD003256. Review.

PMID:
25313415
11.

Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan.

Lin CY, Chen MY, Hsieh SM, Sheng WH, Sun HY, Lo YC, Hung CC, Chang SC.

J Microbiol Immunol Infect. 2009 Jun;42(3):227-33.

PMID:
19812856
12.

Management of Kaposi's sarcoma in resource-limited settings in the era of HAART.

Lynen L, Zolfo M, Huyst V, Louis F, Barnardt P, Van de Velde A, De Schacht C, Colebunders R.

AIDS Rev. 2005 Jan-Mar;7(1):13-21. Review.

PMID:
15875657
13.

Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.

Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM.

J Clin Oncol. 2005 Feb 20;23(6):1253-60.

PMID:
15718323
14.

AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.

Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Mena M, Tavio M, Vaccher E, D'Arminio Monforte A, Tirelli U; AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals.

J Clin Oncol. 2003 Aug 1;21(15):2876-82.

PMID:
12885804
15.

Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.

Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D.

J Clin Oncol. 2006 Jul 20;24(21):3408-14.

PMID:
16849755
16.

Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.

Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthé H, de Truchis P, Zucman D, Rouveix E, Saiag P.

AIDS. 2000 May 26;14(8):987-93.

PMID:
10853980
17.

Incidence of Kaposi's sarcoma and associated mortality in Fresno, California, 1998 to 2012.

Mu A, Rutledge J, Mills P, Paul S.

J Int Assoc Provid AIDS Care. 2014 Nov-Dec;13(6):526-8. doi: 10.1177/2325957414531454. Epub 2014 Apr 16.

PMID:
24739208
18.

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.

Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, Deleuze J, Gorin I, Katlama C, Bricaire F, Dupin N.

Br J Cancer. 2006 Apr 10;94(7):1000-6.

19.

Risk factors for Kaposi's sarcoma in HIV-positive subjects in Uganda.

Ziegler JL, Newton R, Katongole-Mbidde E, Mbulataiye S, De Cock K, Wabinga H, Mugerwa J, Katabira E, Jaffe H, Parkin DM, Reeves G, Weiss R, Beral V.

AIDS. 1997 Nov;11(13):1619-26.

PMID:
9365767
20.

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.

Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Bower M, Gazzard B.

AIDS. 2003 Jul 25;17(11):F17-22.

PMID:
12853764

Supplemental Content

Support Center